Jasper Therapeutics (JSPR) News Today $22.07 -0.05 (-0.23%) (As of 11:22 AM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Jasper Therapeutics' (JSPR) Outperform Rating Reiterated at Royal Bank of CanadaRoyal Bank of Canada restated an "outperform" rating and issued a $68.00 target price on shares of Jasper Therapeutics in a research note on Monday.December 23 at 9:09 AM | marketbeat.comFranklin Resources Inc. Sells 118,900 Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR)Franklin Resources Inc. cut its holdings in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) by 17.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 579,636 shares of theDecember 22 at 4:17 AM | marketbeat.comWellington Management Group LLP Buys New Position in Jasper Therapeutics, Inc. (NASDAQ:JSPR)Wellington Management Group LLP purchased a new position in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 23,759 shares of the company's stock, valuedDecember 21 at 3:41 AM | marketbeat.comFmr LLC Acquires Shares of 38,361 Jasper Therapeutics, Inc. (NASDAQ:JSPR)Fmr LLC bought a new position in Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 38,361 shares of the company's stock, valued at approximately $722,000. Fmr LLC ownDecember 18, 2024 | marketbeat.comInsider Selling: Jasper Therapeutics, Inc. (NASDAQ:JSPR) COO Sells 900 Shares of StockDecember 13, 2024 | insidertrades.comVerition Fund Management LLC Makes New $477,000 Investment in Jasper Therapeutics, Inc. (NASDAQ:JSPR)Verition Fund Management LLC acquired a new position in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 25,353 shares of the company's stock,December 12, 2024 | marketbeat.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Consensus Rating of "Buy" from AnalystsJasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) has earned a consensus recommendation of "Buy" from the ten brokerages that are currently covering the firm, MarketBeat.com reports. Ten analysts have rated the stock with a buy recommendation. The average twelve-month price target among brDecember 7, 2024 | marketbeat.comJasper Therapeutics initiated with an Outperform at BMO CapitalDecember 6, 2024 | markets.businessinsider.comBMO Capital Initiates Coverage of Jasper Therapeutics (JSPR) with Outperform RecommendationDecember 6, 2024 | msn.comBMO Capital Markets Initiates Coverage on Jasper Therapeutics (NASDAQ:JSPR)BMO Capital Markets assumed coverage on shares of Jasper Therapeutics in a research note on Friday. They issued an "outperform" rating and a $63.00 target price for the company.December 6, 2024 | marketbeat.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Shares Acquired by Samsara BioCapital LLCSamsara BioCapital LLC boosted its stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) by 11.4% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 584,642 shares of the company's stock after acquiring an additional 59,642 shares during the quarDecember 5, 2024 | marketbeat.comJasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in AsthmaDecember 2, 2024 | globenewswire.comBraidwell LP Takes $9.09 Million Position in Jasper Therapeutics, Inc. (NASDAQ:JSPR)Braidwell LP purchased a new position in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 483,300 shares of the company's stock, valueNovember 29, 2024 | marketbeat.comAlly Bridge Group NY LLC Buys 180,852 Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR)Ally Bridge Group NY LLC lifted its stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) by 82.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 399,466 shares of the company's stock after purchasing an additional 180,852 shareNovember 28, 2024 | marketbeat.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Stock Holdings Lessened by Great Point Partners LLCGreat Point Partners LLC reduced its holdings in Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) by 19.8% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 322,380 shares of the company's stock after selling 79,635 shares during the quarNovember 27, 2024 | marketbeat.comJasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And AsthmaNovember 18, 2024 | seekingalpha.comWe're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn RateNovember 17, 2024 | sg.finance.yahoo.comIs Jasper Therapeutics (JSPR) the Best Multibagger Stock to Buy Heading into 2025?November 16, 2024 | msn.comJasper Therapeutics to Participate at Upcoming Investor ConferencesNovember 13, 2024 | globenewswire.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Consensus Recommendation of "Buy" from AnalystsJasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) has received an average rating of "Buy" from the nine brokerages that are currently covering the stock, MarketBeat reports. Nine investment analysts have rated the stock with a buy rating. The average 12 month target price among brokeragesNovember 12, 2024 | marketbeat.comJasper Therapeutics (JSPR) Gets a Buy from RBC CapitalNovember 9, 2024 | markets.businessinsider.comOppenheimer Sticks to Its Buy Rating for Jasper Therapeutics (JSPR)November 9, 2024 | markets.businessinsider.comAnalysts Bullish on Jasper Therapeutics as Briquilimab Trials Show PromiseNovember 8, 2024 | finance.yahoo.comPositive Expectations and Clinical Success Drive Buy Rating for Jasper TherapeuticsNovember 7, 2024 | markets.businessinsider.comPromising Outlook for Jasper Therapeutics: Buy Rating Reinforced by Advancements in BriquilimabNovember 7, 2024 | markets.businessinsider.comJasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 7, 2024 | globenewswire.comOppenheimer Sticks to Their Buy Rating for Jasper Therapeutics (JSPR)October 29, 2024 | markets.businessinsider.comJasper Therapeutics (NASDAQ:JSPR) Stock, Option ChainOctober 29, 2024 | benzinga.comHC Wainwright Reiterates Buy Rating for Jasper Therapeutics (NASDAQ:JSPR)HC Wainwright reaffirmed a "buy" rating and issued a $65.00 price objective on shares of Jasper Therapeutics in a research note on Thursday.October 24, 2024 | marketbeat.comJasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific MeetingOctober 24, 2024 | globenewswire.comBuy Rating on Jasper Therapeutics Driven by Promising Clinical Developments and Strategic AdvancementsOctober 24, 2024 | markets.businessinsider.comJasper Therapeutics commences open-label extension study of chronic urticariasOctober 23, 2024 | markets.businessinsider.comJasper Therapeutics Announces Further Expansion of Clinical Program in Chronic Spontaneous UrticariaOctober 23, 2024 | markets.businessinsider.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Recommendation of "Buy" from AnalystsJasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) has been given a consensus recommendation of "Buy" by the ten ratings firms that are presently covering the company, MarketBeat.com reports. Ten research analysts have rated the stock with a buy recommendation. The average 1 year target priOctober 18, 2024 | marketbeat.comJasper Therapeutics' (JSPR) "Market Outperform" Rating Reiterated at JMP SecuritiesJMP Securities restated a "market outperform" rating and issued a $70.00 target price on shares of Jasper Therapeutics in a research report on Tuesday.October 15, 2024 | marketbeat.comBuy Rating Affirmed for Jasper Therapeutics Amidst Promising Briquilimab Clinical Data and Market PotentialOctober 15, 2024 | markets.businessinsider.comBuy Rating Maintained on Jasper Therapeutics Amid Promising Briquilimab Efficacy and Favorable Side Effect ProfileOctober 15, 2024 | markets.businessinsider.comJasper Therapeutics Reports Positive Data From SPOTLIGHT Study - Quick FactsOctober 15, 2024 | markets.businessinsider.comJasper Therapeutics, Inc.: Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible UrticariaOctober 14, 2024 | finanznachrichten.deJasper Therapeutics Stock Gains on Strong Briquilimab Trial ResultsOctober 14, 2024 | marketwatch.comPromising SPOTLIGHT Study Results Support Buy Rating for Jasper Therapeutics Amid Briquilimab’s CIndU Treatment SuccessOctober 14, 2024 | markets.businessinsider.comJasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible UrticariaOctober 14, 2024 | globenewswire.comJasper Therapeutics (JSPR) Gets a Buy from OppenheimerOctober 1, 2024 | markets.businessinsider.comJasper Therapeutics (NASDAQ:JSPR) Stock, Short Interest ReportSeptember 27, 2024 | benzinga.comJasper Therapeutics (NASDAQ:JSPR) Stock Quotes, Forecast and News SummarySeptember 27, 2024 | benzinga.comBuy Recommendation: Jasper Therapeutics’ Briquilimab Shows Market Edge with Favorable Safety ProfileSeptember 27, 2024 | markets.businessinsider.comBuy Rating Affirmed for Jasper Therapeutics Amid Promising Briquilimab Prospects and Strategic DevelopmentSeptember 27, 2024 | markets.businessinsider.comJasper Therapeutics (NASDAQ:JSPR) Earns "Market Outperform" Rating from JMP SecuritiesJMP Securities reaffirmed a "market outperform" rating and set a $70.00 price objective on shares of Jasper Therapeutics in a research report on Friday.September 27, 2024 | marketbeat.comBuy Rating on Jasper Therapeutics Focused on Briquilimab’s Efficacy with Reduced ToxicitySeptember 26, 2024 | markets.businessinsider.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Shares Sold by Ally Bridge Group NY LLCAlly Bridge Group NY LLC trimmed its position in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) by 24.6% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 218,614 shares of the company's stockSeptember 23, 2024 | marketbeat.com Get Jasper Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter. Email Address A.I. Trading System Helps Some Traders Pocket $1,100 per DAY! (Ad)What if I told you 60 seconds a day could completely change your life? This AI-powered trading system finds high-probability option trades in less than 60 seconds a day Click HERE to access this powerful AI Trading System JSPR Media Mentions By Week JSPR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. JSPR News Sentiment▼1.170.57▲Average Medical News Sentiment JSPR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. JSPR Articles This Week▼53▲JSPR Articles Average Week Get Jasper Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Septerna News Day One Biopharmaceuticals News Intellia Therapeutics News Arvinas News Spyre Therapeutics News Calliditas Therapeutics AB (publ) News Gyre Therapeutics News ANI Pharmaceuticals News Syndax Pharmaceuticals News Ardelyx News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:JSPR) was last updated on 12/24/2024 by MarketBeat.com Staff From Our Partners"This looks and feels like 2000," says investing legendOur senior analyst Dan Ferris says a new surprise crisis could begin at any moment... and this time, he says i...Stansberry Research | SponsoredA.I. Trading System Helps Some Traders Pocket $1,100 per DAY!What if I told you 60 seconds a day could completely change your life? This AI-powered trading syst...Prosper Trading Academy | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTiny Mineral, Massive Market OpportunityImagine a mineral so small it fits in the palm of your hand... yet its potential could transform the world's f...i2i Marketing Group, LLC | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jasper Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jasper Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free JSPR Stock Alerts